Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437853 | 1.00 | GAA (0.64) | GAAALDH1A1MAPTHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL7601454 | 0.98 | GAA (0.62) | GAAALDH1A1MAPTHTTHSD17B10 | |
| Carbamic Acid SCHEMBL31088316 | 0.94 | GAA (0.58) | GAAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL1936237 | 0.92 | GAA (0.57) | GAAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL29783179 | 0.84 | RAB9A (0.73) | GAAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL21065527 | 0.84 | HTT (0.68) | GAAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL11533429 | 0.84 | CYP2C9 (0.65) | GAAALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL30605657 | 0.83 | GAA (0.49) | GAAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL361384 | 0.83 | SMN1; SMN2 (0.63) | GAAALDH1A1MAPTHTTHSD17B10 | |
| SCHEMBL10405358 | 0.83 | ALDH1A1 (0.58) | GAAALDH1A1MAPTHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3606528-B1 | TRICYCLIC COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2023-10-18 | — | — | EP | claimed |
| CN-112368270-B | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-10-13 | — | — | CN | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| JP-2007509075-A | — | — | 2007-04-12 | — | — | JP | claimed |
| CN-1898234-A | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORP (US) | 2007-01-17 | — | — | CN | claimed |
| EP-1678167-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | Incyte Corporation (US) | 2006-07-12 | — | — | EP | claimed |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | INCYTE CORPORATION | 2005-05-26 | — | — | US | claimed |
| WO-2005037826-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1266900-A1 | Carbamates of rapamycin | Wyeth (US) | 2002-12-18 | — | — | EP | claimed |
| CN-1036591-C | Carbamates of rapamycin | AMERICAN HOME PROD (US) | 1997-12-03 | — | — | CN | claimed |
| CN-1091135-A | The carbamate of Wyeth-Ayerst Laboratories | AMERICAN HOME PROD (US) | 1994-08-24 | — | — | CN | claimed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | claimed |
| US-5302584-A | Immunosuppressants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | GAA 4373/4885ALDH1A1 1598/4885MAPT 1155/4885 |
| US-20050113344-A1 | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases | MMP25, MMP2, MMP14 | GAA 149/4885ALDH1A1 497/4885MAPT 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.